Related Experiment Video
Updated: Jan 16, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
Isoformic PD-1 impedes B cell activation and function in HIV-1 infection
Li Liu1, Jun Fang2, Ruomei Gong2
1AIDS Institute and Department of Microbiology, Pandemic Research Alliance Unit, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, People's Republic of China; Centre for Virology, Vaccinology and Therapeutics Limited, Science Park, Hong Kong, People's Republic of China.
None:
The interaction between PD-1 and PD-L1 inhibits activation of HIV-1-specific CD8+ T cells, yet mechanisms underlying B cell dysfunction in people living with HIV-1 (PLWHs) remain unclear. Here, we identify a key role for Δ42PD-1, an isoform of PD-1, in human B cells. Chronic HIV-1 infection selectively upregulates Δ42PD-1, but not PD-1, in up to 28% of B cells. B cell receptor (BCR) stimulation induces Δ42PD-1 expression, resulting in B cell-cycle arrest and apoptosis. Mechanistically, Δ42PD-1 recruits SHP-1 via its intracellular immunoreceptor tyrosine-based switch motif, leading to AKT1 inhibition and suppression of the AKT1/FOXO1 pathway, thus promoting B cell apoptosis. Notably, targeting Δ42PD-1 with a specific antibody or gene knockdown reduces SHP-1 recruitment, restores AKT1/FOXO1 activation, and enhances B cell proliferation and function, including HIV-1 envelope (ENV)-specific memory B cells. These findings reveal an inhibitory Δ42PD-1-SHP-1 axis and support Δ42PD-1 as a therapeutic target to restore B cell responses in PLWHs.

